MKH Idris, R Hasham, HF Ismail - DARU Journal of Pharmaceutical …, 2022 - Springer
Abstract Background Metabolic syndrome (MetS) is a risk factor for prostate cancer (PCa) progression. Thus, this life-threatening disease demands a proactive treatment strategy …
TT Su, M Donnelly - European Journal of Cancer Care, 2022 - search.ebscohost.com
The article discusses that the Ministry of Health funds the provision and delivery of opportunistic breast cancer (BC) and colorectal cancer (CRC) screening programmes in …
MKH Idris, R Hasham - Journal of Applied Pharmaceutical Science, 2021 - japsonline.com
Metabolic syndrome (MetS) and prostate cancer (PCa) are among the diseases with a concerning prevalence. The reported cases for both medical dilemmas have been steady …
N Jamhuri, S Shaari, B Baharom… - … Journal of Food, 2024 - jurcon.ums.edu.my
Cancer sufferers typically seek a rapid alternative remedy, such as traditional and complementary medicine (TCM). Reliable data on the prevalence and patterns of TCM …
The discovery and identification of new safe drugs that are specifically cytotoxic against cancer cells becomes an important target in cancer research. Increasing number of cancer …